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ABSTRACT: Fatty acid amide hydrolase (FAAH) is an important drug target for the treatment of many disease related conditions 
such as pain, inflammation and mood disorders due to its vital role in the metabolism of endocannabinoid. In our present work, a 
FAAH-activated fluorescent probe named THPO was developed which possessed high selectivity and excellent sensitivity for FAAH 
in complex systems. Critically, its metabolite AHPO has long excitation and emission wavelengths and high fluorescence quantum 
yield which are necessary for monitoring the activity of FAAH in living systems. In addition, a visual high-throughput screening 
method for FAAH inhibitors was established using THPO which resulted in the discovery of an efficient natural inhibitor 
Neobavaisoflavone that was identified from 68 traditional herbal medicines. These results indicated that THPO can be used as a 
molecular tool for the rapid evaluation of FAAH activity in complex systems as well as providing an effective approach to screen 
FAAH inhibitors and providing a boost for the discovery of therapeutic agents toward FAAH related diseases.   
 
INTRODUCTION 
Fatty acid amide hydrolase (FAAH) is a key bioactive protein, 
it belongs to a large family of enzymes that shares a highly 
conserved 130 amino acid motif designated the “amidase 
signature” sequence and has an extensive expression in the 
brain and some other tissues.1-5 FAAH catalyzes the hydrolysis 
of some biologically active amides and agonists of the 
peroxisome proliferator-activated receptors.6 It is mainly 
responsible for the inactivation of fatty acid ethanolamides 
(FAEs), in particular, catalyzing the hydrolysis reaction of 
arachidonoylethanolamide (AEA) to arachidonic acid and 
ethanolamine terminating signal transduction.7-9 AEA is the 
most comprehensively investigated endocannabinoid which is 
involved in a variety of biological functions related to pain and 
inflammation.10,11 Thus, FAAH plays an important role in 
various conditions for instance: inflammation, neuropathic pain, 
nonsmall cell lung cancer and Alzheimer’s disease. All these 
diseases are related to the hydrolysis process of AEA, due to the 
powerful ripple effect mediated by AEA, and AEA not only 
modulates nociception, but also attenuates neutrophil migration 
and immue-cell recruitment during inflammation, through 
activation of CB1 and CB2 receptors.9,12-14 Therefore, the 
discovery of ‘classical’ FAAH inhibitors as well as the 
development of molecular tools for rapidly evaluating the 
FAAH activity in complex systems are urgently required. Such 
molecular tools would facilitate rapid and accurate 
measurement of FAAH activity and further determine efficient 
inhibitors for treatment of various diseases.15-19 Recently, some 
FAAH inhibitors were designed and developed such as PF-
04457845, URB597, URB524, and BMS-1.20-22 Though these 
inhibitors exhibited good activity in cell and animal models, 
they all exhibited significant side effects such as the failure of 
PF-04457845 (FAAH inhibitor) in the Phase II study on 
osteoarthritic pain.23 Therefore, nontoxic and effective FAAH 
inhibitors as potential medicines are urgently needed for clinical 
use; all of these studies require an effective method for the high-
throughput screening of FAAH inhibitors. 
Fluorescence techniques have been widely used for enzyme-
related drug screening and disease diagnosis with many 
advantages including sensitive, real-time detection, high 
spatiotemporal resolution, and noninvasive monitoring efficacy 
in various living systems as well as high-throughput screening 
capability.24-30 Recently, some fluorescent probes for FAAH 
have been developed,31-35 however, challenges including short 
emission wavelength has limited their applicability in complex 
biological systems for screening inhibitors. Additionally 
luciferase-dependent probes require luciferase expression in 
complex biological systems, importantly; it was hardly to 
distinguish the final inhibition activity was dependent on 
inhibiting the FAAH or luciferase, all of which limits the 
practical applications of these probes.34,35 Therefore, 
developing long-wavelength fluorescent probe for selectively 
and sensitively monitoring endogenous FAAH activity in 
complex biological systems and establishing visual high-
throughput screening methods for the discovery of FAAH 
inhibitors are urgently needed. 
Herein we developed a fluorescent substrate (THPO) for 
FAAH (Scheme 1), by introducing arachidonic acid as a 
specific recognition moiety for FAAH into the skeleton of 7-
amino-3H-phenoxazin-3-one (AHPO). As expected, THPO 
possesses some prominent advantages: firstly, the metabolite 
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AHPO not only has red-emission wavelength (λex/λem = 
550/592 nm) but also possesses high fluorescence quantum 
yield; secondary, THPO exhibited high specificity and 
sensitivity toward FAAH among various hydrolase enzymes; 
thirdly, THPO can be applied for monitoring and imaging of 
FAAH in living cells, as well as establishing a visual high-
throughput screening platform for novel FAAH inhibitors from 
herbs. In a word, THPO could act as a promising tool in the 
rapid evaluation of FAAH activity in complex systems, and the 
screening of FAAH inhibitors for the development of clinical 
agents. 
 
Scheme 1. The mechanism of THPO catalyzed by FAAH.  
EXPERIMENTAL SECTION 
Materials and instruments. Fatty acid amide hydrolase used in 
this experiment was expressed in 293T cells. SH-SY5Y cells 
were purchased from American Type Culture Collection. 
Trypsin (Try), Lysozyme (Ls), Proteinase K (PaK), Carbonic 
anhydrase (Cas), N-acetyl glucosaminidase (NAG), Proline 
aminopeptidase (PAP), β-Galactosidase (β-Gla), Dipeptidyl 
Peptidase 4 (DPP4), β-Glucosidase (β-Glc), β-Glucuronidase 
(β-Glu), Lipase, and were all obtained from Sigma-Aldrich. 
Glycine, Glutamate, Arginine, Glutamine, Tryptophan, Serine, 
Glutathione, Myristic acid, Tyrosine, Cysteine, Glucose, and 
lysine were purchased from Shanghai Yuanye (Shanghai, 
China). URB597 was purchased from Selleckchem. BCA 
Protein Quantitation Kit was purchased from Beyotime 
(Shanghai, China). All other reagents and solvents used were of 
the highest grade commercially available. All fluorescence 
analysis were conducted on Synergy H1 Microplate Reader 
(Bio-Tek). NMR spectra were required using Bruker-600. 
HRMS detection was measured on G6224A TOF MS. The 
hydrolysis supernatants were determined by HPLC-UV 
analysis (Waters e2695 equipped PDA Detector). The HPLC 
fractions of Psoralea corylifolia Linn. were obtained by HPLC 
(Waters 2767 Sample Manager with Waters 2489 UV Detector). 
Synthesis pathway for THPO. The starting material of 7-
amino-3H-phenoxazin-3-one (AHPO) was prepared following 
the reported procedure.36 (Figure S1). Arachidonic acid (72 mg, 
0.24 mmol), EDCI (136 mg, 0.72 mmol) and DMAP (58 mg, 
0.48 mmol) were dissolved in CH2Cl2 (5 mL). Then a solution 
of AHPO (50 mg, 0.24 mmol) in THF (5 mL) was added slowly. 
The resulting mixture was stirred at room temperature for an 
additional 24 h, and then the solvent was removed under 
reduced pressure, the crude product was purified by silica gel 
chromatography (ethyl acetate/petroleum ether = 1:2) to obtain 
the product as red solid (16 mg, 13% yield). 1H NMR (600 MHz, 
DMSO-d6) δ 10.53 (s, 1H), 7.96 (d, J = 2.2 Hz, 1H), 7.78 (d, J 
= 8.7 Hz, 1H), 7.53 (d, J = 9.8 Hz, 1H), 7.49 (dd, J = 8.8, 2.2 
Hz, 1H), 6.79 (dd, J = 9.8, 2.1 Hz, 1H), 6.29 (d, J = 2.1 Hz, 1H), 
5.56 – 5.11 (m, 8H), 2.76 (ddd, J = 26.5, 12.1, 6.2 Hz, 6H), 2.40 
(t, J = 7.3 Hz, 2H), 2.10 (dd, J = 13.8, 6.8 Hz, 2H), 1.98 (dd, J 
= 14.1, 7.0 Hz, 2H), 1.73 – 1.63 (m, 2H), 1.33 – 1.13 (m, 6H), 
0.83 (t, J = 7.0 Hz, 3H).13C NMR (150 MHz, DMSO-d6) 
δ184.76, 171.51, 149.19, 145.31, 143.80, 143.04, 134.29, 
133.27, 130.10, 129.29, 128.60, 128.47, 127.74, 127.44, 127.35, 
127.15, 127.02, 126.85, 115.77, 105.18, 104.05, 39.44, 35.25, 
30.26, 28.09, 25.96, 25.48, 24.61, 24.56, 24.02, 21.36, 13.31. 
HRMS (ESI positive) calcd for [M+H]+ 499.2955, found 
499.2947. All the NMR and HRMS data were shown in Figure 
S2-4. 
Expression, purification and characterization of recombinant 
FAAH. The vector for FAAH production, FAAH-HIS pCDH-
PURO was constructed with the primers FAAH_F (5’–
GATTCTAGAGCTAGCGAATTCGCCACCATGGTGCAGT
ACGAGCTG–3’), FAAH_R (5’–
GCCGCGGATCCGATTTAAATTTAGTGGTGGTGGTGGT
GGTGCTCGAGGGATGACTGCTTTTCAGGGGTC–3’), 
and the HIS tag was attached to the c-terminal of the target gene. 
After verification of the sequence, the recombinant plasmid was 
transfected into 293T cells, the cells were harvested by scraping 
48 h post-transfection, disrupted by sonication in an ice bath 
and the cell debris was removed by centrifugation at 10,000 g 
and 4 °C for 10 min. Next, the recombinant FAAH was purified 
as the previous reports.37,38 Briefly, the cleared supernatant was 
immediately applied to 1 mL of Ni-NTA resin loaded in a 
column which was pre-equilibrated with binding buffer. The 
resin was subsequently washed with 10 mL washing buffer. 
Elution was carried out with 5 mL elution buffer. The protein 
purification was performed under the flow rate of 1 mL/min and 
the temperature of 4 °C. Finally, the recombinant protein was 
desalted in desalting buffer by 3 cycles of concentration and 
obtained using Amicon Ultra-30K and stored at −80 ºC. Protein 
purity was confirmed by SDS-PAGE to be > 80% and protein 
concentration for all studies was determined by the Protein 
Quantitative Kit. All the Protein purity data were shown in 
Figure S5-6. 
Incubation conditions and analysis method. In order to 
characterize the spectral characteristic of THPO and its 
fluorescence response toward FAAH, the whole system with a 
total volume of 200 μL containing Tris-EDTA-BSA buffer (125 
mM Tris-Hcl, 1 mM EDTA, 0.1% BSA, pH = 8), THPO and 
FAAH. In brief, THPO (10 μM) was added after preincubation 
of FAAH in the standard system at 37 °C for 3 min. Organic 
solvent (DMSO) was not more than 1% (v/v). The incubation 
reaction was performed at 37 °C for 30 min, and then terminated 
by adding 100 μL ice-cold acetonitrile, followed by 
centrifugation for 20 min at 4 °C at 20,000 g.29 The supernatant 
was subjected to Synergy H1 Reader (Bio-Tek) and HPLC 
analysis. Additionally, the control experiment without FAAH 
was performed in a similar way to make sure that metabolite 
formation was FAAH-dependent. We also explored the 
relationship of fluorescence intensity change of THPO toward 
FAAH following the change of enzyme concentration and the 
reaction time, respectively. All assays were performed three 
times. 
Screening the selectivity of THPO. The selectivity of THPO 
toward FAAH was evaluated, briefly, THPO was incubated 
with various enzymes including Try, Ls, PaK, Cas, NAG, β-Gla, 
β-Glc, β-Glu, PAP, Lipase and DPP4 in the standard incubation 
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system at 37 °C for 30 min with the final enzyme concentration 
at 15 μg/mL, respectively. Furthermore, we also examined the 
influence of common metal ions such as positive ions K+, Ca2+, 
Zn2+, Fe3+, Mn2+, Sn2+, Mg2+, Cu2+, Ni+, Ba2+, Na+; negative ions 
like NO3
-, CO3
2-, SO4
2-, and some amino acids: Serine, 
Glutamate, Glucose, Glutamine, Glycine, Glutathione, 
Tyrosine, Arginine, Lysine, Cysteine, Tryptophan, and Myristic 
acid on the fluorescence intensity of THPO and AHPO in the 
standard incubation system with the final concentration of 10 
μM, respectively29. Finally, the supernatant was subjected to 
Synergy H1 Reader for analysis and all assays were performed 
three times. 
Kinetics Study. The kinetic parameters are very important for 
the application of the probe and also illustrate the affinity of the 
substrate towards the enzymes. Therefore, we conducted the 
kinetic study to estimate the kinetic constants of THPO for 
FAAH. In brief, THPO (0 – 100 μM) was incubated with 
FAAH (15 μg/mL) for 30 min. The incubation times and protein 
concentrations were selected in the linear range.29 The apparent 
Km and Vmax values were calculated from nonlinear regression 
analysis of experimental data according to Michaelis-Menton 
(1). 
𝑉 = 𝑉𝑚𝑎𝑥
[𝑆]
𝐾𝑚+[𝑆]
………………………………………………… (1) 
The Vmax represents the maximal catalytic velocity and Km is the 
substrate concentration with the half-maximal rate which 
represents the affinity of THPO. Kinetic constants were 
obtained using GraphPad Prism 6 and produced as the mean ± 
SD of the parameter estimate.29 
Chemical Inhibition. To further validate the specific property 
of THPO toward FAAH, we performed chemical inhibition 
experiments. THPO (10 μM) was incubated with various 
hydrolase inhibitors including Baicalin (100 μM), LPA (100 
μM), KCZ (100 μM), Biochain A (1 μM) and URB597 (10 nM) 
in the standard incubation system at 37 °C for 30 min with the 
final brain S9 concentration at 20 μg/mL, respectively. Finally, 
the supernatant was subjected to Synergy H1 Reader for 
analysis and all assays were performed three times. 
The fluorescence imaging of FAAH in living cells. Firstly, 
cytotoxicity was evaluated using the CCK-8 assay (Roche 
Diagnosis, Indianapolis, IN). In brief, SH-SY5Y cells were 
seeded in a 96-well plate with the final concentration of 5 × 103 
cells were seeded in each vial. Then FBS free culture medium 
containing various concentrations of THPO was added (0, 1, 2, 
5, 10, 20, 50 and 100 μM), the control group used blank solvent 
without THPO. After 24 hours incubation, the culture medium 
was discarded and FBS free culture medium with 10% (v/v) 
CCK-8 was added.39 After one-hour incubation, the plate was 
detected at 450 nm in a Synergy H1 Reader (Bio-Tek). Cell 
viability of the samples without THPO was considered to be 
100%.29 Next, the imaging ability of THPO in SHSY-5Y cells 
was evaluated. Briefly, SHSY-5Y cells were cultured in RPMI-
1640 medium with fetal bovine serum (FBS) of 10% in an 
atmosphere of 5% CO2 at 37 °C. Next, the cells were reseeded 
on 10 mm coverslip in 6-well plate at a concentration of 2×105 
cells mL-1. After SHSY-5Y cells were attached, the adherent 
cells were incubated with THPO (20 μM) for 60 min at 37 °C 
in a 5% CO2 incubator, additionally another group was 
pretreated with URB597 (5 μM, prepared in medium containing 
5% FBS) for 30 min and then incubated with THPO under the 
same condition mentioned above. Then, the residual THPO 
was removed and imaged using a confocal microscope (Leica 
TCS SP8) with the excitation laser at 561 nm and acquisition 
wavelength at 575 – 630 nm. 
Visual high-throughput screening of FAAH inhibitor from 
herbal medicines. In order to investigate the inhibitory effects 
of natural products of herbal drugs towards FAAH, a high-
throughput screening method was developed using THPO in 
vitro. Due to the abundant expression of FAAH in rat brain,8,11 
and our results indicated that the inhibition activity of URB597 
(classic selective inhibitor for FAAH) in Brain S9 was very 
close with the recombinant FAAH (IC50: 7.84 ± 0.031 nM vs 
3.45 ± 0.001 nM). Thus, Rat brain S9 (20 μg/mL) was used as 
the enzyme resource in the high-throughput screening. Firstly, 
the extracts of 68 kinds herbal medicines were obtained as 
follows (Table S1): each herb (5 g of dried plant sample) was 
accurately weighted and ground to fine particles, and then 
passed through a 40-mesh screen. After which, they were 
extracted with 95% ethanol (100 mL) by ultrasonication at room 
temperature for 60 min, respectively; and the extraction process 
was repeated for three times, and the extracts were filtered in 
vacuo and then collected and evaporated. Then, the dried extract 
was dissolved in DMSO 20 mg/mL as a stock solution, these 
extracts of 68 herbal medicines were added to our standard 
system in the presence of THPO (10 μM) at the finial 
concentration of 20 μg/mL (containing less than 1% DMSO), 
respectively. The same volume of DMSO instead of herbal 
extract as the control group was added in the same incubation 
system. Finally, after incubation at 37 °C for 30 min, 100 μL 
ice-cold acetonitrile was added to terminate the reaction. The 
supernatant was transferred to a 96-well plate and imaged in GE 
Typhoon FLA9500 with an excitation laser of 532 nm equipped 
with the emission filter of 570 ± 10 nm. The residual activity 
was analyzed semi-quantitatively by fluorescence imaging. 
Meanwhile the samples were also tested by Synergy H1 reader 
(Bio-Tek), and the residual activity was calculated, the control 
group without herb medicines was considered as 100%. 
Isolation and identification of the key inhibitory compound of 
Psoralea corylifolia Linn. toward FAAH. The fruits of 
Psoralea corylifolia Linn. (2 kg) were powdered and extracted 
using ethanol reflux (10 L × 3). After the evaporation of ethanol, 
the HPLC fractions of extracts were obtained using an efficient 
HPLC method (the mobile phase consisted of 10% acetonitrile 
+ 90% trifluoroacetic acid water (A) and acetonitrile (B) at a 
flow rate of 10 mL/min. The following gradient condition was 
used: 0 – 10 min 75% A; 10 – 50 min 75% – 10% A; 50 – 55 
min 10% – 75% A; 55 – 75 min 75% A.), several fractions were 
collected, and then the inhibitory effects of these fractions were 
evaluated by the above method using THPO (10 μM) and Rat 
Brain S9 (20 μg/mL). Additionally, in order to confirm the 
inhibitory nature of the fractions on the FAAH, the inhibition 
activity of the 13 fractions on the classic hydrolysis reaction of 
AEA which in catalyzed by FAAH in human was also 
performed. In brief, Fractions (2.5 μg/mL) and cannabinoid (10 
μM) was incubated with rat brain S9 (40 μg/mL) in the standard 
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incubation system at 37 °C for 60 min. Finally, the supernatant 
was subjected to LC-MS for analysis. The HPLC analysis 
method was as follows: the mobile phase consisted of 
acetonitrile (B) and 0.1% formic acid aqueous solution (C) at a 
flow rate of 0.5 mL/min. The following gradient condition was 
used: 0 – 7 min 20% B The negative mode was used with the 
following values: AA (Q1→Q3：303.0 → 303.0). Fr. 5 was 
confirmed as a potent inhibition fraction and the key compound 
in Fr. 5 was isolated and purified by the HPLC (60% Methanol: 
40% trifluoroacetic acid water) equipped with DAD detector 
and ODS column (Agela Innoval ODS-2, 4.6 mm × 250 mm, 5 
μm), the potential inhibitor was purified from the bioactive 
fraction using preparative HPLC as L-BGZ. Subsequently, the 
IC50 values of Neobavaisoflavone and the previously reported 
natural inhibitor Biochanin A for THPO were determined. 
Inhibitors (0 – 20 μM) and THPO (10 μM) was incubated with 
FAAH (20 μg/mL) for 30 min. Finally, the supernatant was 
subjected to Synergy H1 Reader for analysis. IC50 refers to the 
inhibitor concentration at which residual activity reaches 50%. 
Data were obtained using GraphPad Prism 6 and all tests were 
repeated three times. 
Molecular docking. Discovery Studio 3.5 was employed by 
docking the ligands to FAAH1. The structure of human FAAH1 
was built by homologous modeling based on the template of 
Rattus norvegicus FAAH1 (PDB code: 2WJ1) 40. The active 
binding site was defined according to the reference ligand with 
a radius of 8.5 Å. The protein structure was processed by adding 
hydrogen atoms, removing water, and assigning Charmm 
forcefield. The gold score was selected as the score function, 
and the other parameters were set as default. A maximum of 20 
conformations were generated. 30 ligand poses were allowed to 
be saved with a minimum RMSD between final poses of 0.50 
Å 41. 
RESULTS AND DISCUSSIONS 
Spectral properties of THPO toward FAAH. Firstly, human 
recombinant expression FAAH was obtained in HEK293T cells 
which overexpressed FAAH. Then, after incubating with 
FAAH, the spectral properties of THPO exhibited a significant 
change, as shown in Figure 1A-B, and Figure S7; a remarkable 
enhancement of the absorption at 560 nm was detected, 
followed by a significant increase in the fluorescence signal at 
592 nm. The incubated samples were analyzed using HPLC, as 
shown in Figure S8, a new chromatographic peak was observed 
after incubating with FAAH (THPO 10 μM was incubated with 
FAAH (25 μg/mL) in the standard incubation system at 37 °C 
for 60 min.), electrospray ionization (ESI) mass spectra of the 
reaction product resulted in [M+H]+ ion peak at m/z 213.2 
which was identified as AHPO. Additionally, the reaction 
exhibited good enzyme linear range from 0 – 45 μg/mL (Figure 
1) and a linear time-dependent  
 
Figure 1. The absorbance (A) and fluorescence (B) spectra 
response of THPO after incubating with FAAH (25 μg/mL) at 
37 °C for 30 min; The fluorescence spectra response (C) and 
liner relationship (D) of fluorescence intensity at 592 nm toward 
the increasing of the concentration of FAAH. 
(Figure S9). As shown in Figure S10, the influence of pH on 
the fluorescence intensity of THPO and AHPO indicated that 
the metabolite AHPO exhibited a stable fluorescence emission 
under physiological conditions. All the above results clearly 
demonstrated that the fluorescence of THPO displayed turn-on 
when metabolized by FAAH. 
Screening the selectivity of THPO toward FAAH. Next, the 
specificity for THPO among some major human metabolic 
enzymes was investigated. As shown in Figure S11A, THPO 
was a selective substrate for FAAH and displayed a significant 
fluorescence response, while other enzymes including Try, Ls, 
PaK, Cas, NAG, β-Gla, β-Glc, β-Glu, PAP, lipase, and DPP4 
had no fluorescence response. Additionally, THPO and AHPO 
could not be influenced by common endogenous substances, 
metal ion and some negative ions including: GSH, Lys, Gly, 
Glucose, Tyr, Myristic acid, Gln, Cys, Trp, Ser, Glu, Arg, and 
Na+, Ca2+, K+, Zn2+, Ni+, Mn2+, Mg2+, Fe3+, Ba2+, Cu2+, Sn2+, 
CO3
2-, SO4
2-, and NO3
-  (Figure S11B, S12). 
Kinetics Study. A kinetic analysis was performed to obtain the 
characteristic of THPO for detecting FAAH. As shown in 
Figure S13, the metabolism of THPO mediated by FAAH 
exhibited Michaelis-Menton kinetics model and the Km was 
1.84 ± 0.14 μM, Vmax = 0.227 ± 0.003 nmol/mg/min. The kinetic 
evaluation indicated that THPO had a high affinity toward 
FAAH which made it efficient in detecting FAAH activity in 
complex biological samples. Importantly, after introducing 
URB597 and Biochanin A as the highly selective inhibitors for 
FAAH, the fluorescence response could be significantly 
blocked, while other inhibitors such as Loperamide 
hydrochloride (LPA, the selective inhibitor for CES2), 
Ketoconazole (KCZ, CYP3As inhibitor), and baicalin (β-
Glucuronidase inhibitor) produced only slight inhibitory effects 
on the fluorescence response (Figure S14). All the above 
results fully demonstrated that THPO can serve as a highly 
sensitive and selective fluorescent tool to measure FAAH 
activity. 
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Figure 2. Confocal fluorescence images of FAAH in living 
cells. (A – C) the confocal fluorescence background images of 
SHSY-5Y at 575 – 630 nm with 561 nm excitation; (D – F) the 
confocal fluorescence images of SHSY-5Y cells after 
incubating with THPO; (H – J) the confocal fluorescence 
images at of SHSY-5Y cells pretreated with URB597 and 
stained with THPO. Scale bars 25 μm. 
Fluorescence imaging of FAAH in living cells. FAAH is 
expressed in nerve cell in brain, and mediates the hydrolysis of 
cannabinoids.8, 11 Therefore, in the current study; the 
fluorescence imaging of FAAH in SHSY-5Y cells was 
evaluated. Firstly, THPO displayed no cytotoxicity for SHSY-
5Y up to 100 μM (Figure S15). Then, after incubating THPO 
(20 μM) with SHSY-5Y cells for 1 h at 37 °C, the cells 
displayed significant fluorescence intensity in the red channel 
(575 – 630 nm), while the group pretreated with URB597 (5 
μM) had weak fluorescence response (Figure 2). These results 
indicated that THPO had good cell permeability and specificity 
for real-time monitoring of FAAH activity in living cells. These 
results indicated that THPO could serve as an efficient and 
selective tool for detecting FAAH activity in complex 
biological systems. 
Visual high-throughput screening of FAAH inhibitor from 
herbal medicines. FAAH has been determined as a suitable 
drug target in the treatment for many disease related conditions 
including pain, inflammation and mood disorders. 3,16,18 In order 
to discover suitable lead compounds for further study, we 
screened for FAAH inhibitors from herbal medicines. As shown 
in Figure 3A-C, 68 kinds of herbal medicines were used for the 
visual high-throughput screening approach (Table S1), among 
which Psoralea corylifolia Linn. (herb. 41) exhibited 
significant inhibition at 20 μg/mL. While other herbs including 
rhizoma alismatis, motherwort, ginkgo leaf, liquorice displayed 
only slight inhibitory effect. Thus, Psoralea corylifolia Linn. 
was chosen for further study. These results indicate that THPO 
can be used as a promising tool for visual high-throughput 
screening of FAAH inhibitors. Next, as shown in Figure 4, 13 
fractions were collected according to the HPLC chromatogram 
of Psoralea corylifolia Linn. and their inhibitory effects toward 
FAAH were evaluated using the method mentioned above.  
 
Figure 3. (A) Visual high-throughput fluorescence image of the 
inhibitory effects of 68 kinds of herbs toward FAAH assayed 
using THPO; (B, C) the inhibitory effects on FAAH measured 
using THPO by microplate reader (red, λex 550 nm, λem 592 
nm), and the remaining FAAH activity (black) based on the 
relative fluorescence intensity of fluorescence images (A) in 
each well of 96-well plate. 
 
Figure 4. (A) HPLC fractions of Psoralea corylifolia Linn.; (B) 
fluorescence image of the inhibitory effects of 13 fractions 
separated from Psoralea corylifolia Linn. toward FAAH 
assayed using THPO; (C) the inhibitory effects on FAAH 
measured using a microplate reader (red, λex 550 nm, λem 592 
nm), and the remaining FAAH activity (black) based on the 
relative fluorescence intensity of fluorescence images (B) in 
each well of 96-well plate. 
Interestingly, varying degrees of inhibitory effects were 
observed from different fractions. Briefly, among various 
fractions, Fr. 5 exhibited the strongest inhibition toward FAAH 
when compared with the others, which produced a residual 
activity of 18.41% at a concentration of 2.5 μg/mL. Compared 
with Fr. 5, Fr. 10 and Fr. 12 displayed inhibition with residual 
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activity of 29.98% and 28.08%, respectively. While, other 
fractions including Fr. 2, Fr. 4, Fr. 6, Fr. 7, Fr. 8 and Fr. 9 all 
displayed less inhibition (residual activity > 35%). Fr. 3 and Fr. 
13 exhibited a very weak inhibition (residual activity > 70%), 
Fr. 1 had almost no inhibition activity. 
Isolation and identification of the key inhibitory compound of 
Psoralea corylifolia Linn. toward FAAH. As shown in Figure 
S16, the inhibition activity of 13 fractions was also confirmed 
by the classic hydrolysis reaction of AEA. Consistent with the 
previous study, Fr. 5 also exhibited a potent inhibitory activity 
on FAAH. Thus, the target compound (L-BGZ) in Fr. 5 was 
isolated, next, on the basis of spectroscopic data, including 1H 
NMR, 13C NMR and HRMS; finally, L-BGZ was determined 
to be an isoflavone derivative possessing an isopentene group. 
(Figure S17 – 19, Table S2) Compared with the previously 
reported spectroscopic data, L-BGZ was determined to be 
Neobavaisoflavone. Next, the inhibitory effect of 
Neobavaisoflavone was evaluated. As shown in Figure 5, this 
novel natural inhibitor of FAAH exhibited much higher 
inhibition activity than Biochanin A, a previously reported 
natural inhibitor (IC50: 131.6 ± 5.12 nmol vs 714.5 ± 44.13 nmol) 
toward FAAH. These results confirmed that THPO has great 
superiority in the screening of FAAH inhibitors and 
Neobavaisoflavone could serve as a novel natural FAAH 
inhibitor for further investigation of its biological function. 
Molecular docking. To explore the potential binding model of 
Neobavaisoflavone and FAAH, molecular docking was 
performed using Discovery Studio 3.5 to provide an insight into 
any potential interactions. As presented in Figure 6B and C, 
Neobavaisoflavone could occupy the binding pocket. The 
hydroxyl group at the 7-position of Neobavaisoflavone could 
form a hydrogen bond with Thr488 located at the entrance of 
the active site, an important alpha helix. Another key hydrogen 
bond was observed between the B ring carbonyl group of 
Neobavaisoflavone and the side chain of Tyr194. The phenyl 
moiety (A ring) of Neobavaisoflavone initiated a Pi-Alkyl 
interaction with Leu404. Additionally, the B ring carbonyl 
group of Neobavaisoflavone of Y29 interacts with residues 
Ile238, Ser241 and Gly239, resulting in three key hydrogen 
bond interactions, which anchors the ligand in the binding 
pocket. While the isopentene group is deeply embedded in a 
hydrophobic pocket including Met191, Leu278, and Ile238 
residues facilitated by hydrophobic interactions. The above 
results provide the structural basis for Neobavaisoflavone as a 
potent FAAH inhibitor. 
 
Figure 5. (A) The inhibitory effects of Neobavaisoflavone and 
Biochanin A with increasing concentration; (B) the IC50 values 
of Neobavaisoflavone and Biochanin A. 
 
Figure 6. (A) The homology model of human FAAH; (B) 
Molecule docking of Neobavaisoflavone and FAAH; (C) 
Detaild for the interaction between Neobavaisoflavone and 
FAAH. 
CONCLUSIONS 
In summary, based on the catalytic mechanism of FAAH, we 
successfully developed a novel enzyme-activated fluorescent 
probe named THPO which possessing high selectivity and 
sensitivity toward FAAH among various enzymes. The kinetic 
parameters indicated that THPO had a very high affinity toward 
FAAH, which made it suitable in the measurement of FAAH 
activity in complex systems. Importantly, a visual high-
throughput screening method for FAAH inhibitors was 
established using THPO and a novel natural efficient FAAH 
inhibitor Neobavaisoflavone was discovered and identified 
from 68 herb medicines. These results fully demonstrated the 
potential utility of THPO in investigating the physiological 
function of FAAH in living systems, as well as providing a 
novel method for the rapid screening of FAAH inhibitors with 
therapeutic potential for various diseases associated with 
FAAH. 
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